NUS Public Health Programs: Cultivating Leaders for a Changing World
Offered by the Saw Swee Hock School of Public Health, the Master of Public Health (MPH) and the upcoming MSc in Health Economics and Outcomes Research (HEOR) reflect NUS’s commitment to global relevance, academic rigor and industry-aligned training.
Meeting the region’s public health priorities
Frist launched in 2007, the MPH program is one of Asia’s most established pathways into public health leadership. Its focus is regional,but its standards are global. It combines foundational knowledge with applied skills across areas such as epidemiology, biostatistics, policy progress and more.
“Compared to programs that focus narrowly on one area, the MPH is broader by design,” said associate professor Mary Chong.”We emphasize integration and systems thinking so that graduates are equipped to lead across sectors. But there’s also room to specialize and go deep into specific domains when needed.”
Mary also highlighted the value of NUS’s strong regional and global networks. “NUS’ global rankings, world-class faculty, and robust research infrastructure give students access to an academic ecosystem that is both deep and wide,” she said.
This exposure to regional and international collaborations helps cultivate public health leaders who are adaptable, thoughtful and equipped to drive meaningful change in public health.
Furthermore, the requirement of one to two years’ work experience ensures that students bring practical insights into the classroom, enriching discussions and group learning throughout the program.
at the heart of the MPH is an eight-week practicum that gives students the chance to apply their learning to real-world public health challenges. They identify a topic aligned with their interests, from mental health in the elderly to youth vaping and work under the guidance of a faculty supervisor.
“The practicum strengthens their ability to communicate public health findings both orally and in writing, which is especially critically important when they’re acting as a bridge between policymakers and the public,” said Mary. One recent project involved analyzing Singapore’s Nutri-Grade labelling system for sugar-sweetened beverages, showing how students tackle issues directly relevant to policy and practice.
Collaborative by nature. Students are encouraged to further their discussions outside the classroom to build peer learning and outlook. (Courtesy of National University of Singapore)
The Growing Importance of Health Economics and Outcomes Research in Maximizing the impact of New Drugs
The development of new drugs represents a significant investment and holds the promise of improved health outcomes. However, simply having a new treatment available isn’t enough. Understanding the clinical and economic impact of new drugs – including how they help patients and caregivers stay productive longer – is crucial for healthcare systems, policymakers, and the pharmaceutical industry alike. This is where the field of Health Economics and Outcomes Research (HEOR) plays a vital role.
The Clinical Impact: Beyond Efficacy
traditionally, drug approval focused heavily on clinical efficacy – does the drug work? Today, the focus is expanding. Clinical impact now encompasses a broader view, including:
* Severity of Illness Modification: Does the drug reduce the severity of symptoms and disease progression?
* Improved Quality of Life: How does the drug impact a patient’s daily functioning, emotional well-being, and overall quality of life? Patient-Reported Outcomes (PROs) are increasingly critically important in this assessment. https://www.fda.gov/patients/patient-reported-outcome-measures
* Reduced Morbidity & Mortality: Does the drug reduce the incidence of complications or death?
* Pharmacogenomics & Personalized Medicine: Understanding how a patient’s genetic makeup influences their response to a drug allows for more targeted and effective treatment. https://www.genome.gov/about-genomics/precision-medicine
The Economic Impact: Value for Money
Alongside clinical benefits, evaluating the economic impact of new drugs is essential. This involves assessing:
* Cost-Effectiveness: Determining whether the clinical benefits of a drug justify its cost. This is often expressed as a cost per Quality-Adjusted Life Year (QALY) gained. https://www.cdc.gov/tobacco/campaign/truth/pdfs/cost-effectiveness.pdf
* Budget Impact: Analyzing the overall financial impact of a new drug on healthcare budgets, considering factors like patient population size, drug price, and potential changes in healthcare utilization.
* Return on Investment (ROI): For pharmaceutical companies,assessing the financial return on their investment in research and development.
* Productivity Gains: A critical, often overlooked aspect is the impact on patient and caregiver productivity. New drugs that allow patients to manage their conditions more effectively can enable them to remain in the workforce longer, contributing to the economy. Similarly, reducing the burden of caregiving allows caregivers to maintain their own employment and economic activity. This is particularly important in the context of chronic diseases.
The Role of HEOR Professionals
The National university of Singapore (NUS) offers programs in both Master of Public Health (MPH) and Master of Science in Health Economics and outcomes Research (MScHEOR) designed to equip professionals with the skills to navigate this complex landscape. https://sph.nus.edu.sg/?utm_source=JakartaPost&utm_medium=Artilce&utm_campaign=MPH%2BMScHEORGeneralPromo These programs emphasize real-world request and preparing students to contribute to healthcare resource allocation and value assessment.
HEOR professionals utilize a variety of methodologies, including:
* Cost-Effectiveness Analysis (CEA)
* Budget Impact Modeling
* Decision Analytic Modeling
* Statistical Analysis of Healthcare Data
* Systematic Literature Reviews
Global Relevance, Regional Focus
The need for skilled HEOR professionals is global, but particularly acute in Asia, where healthcare systems are rapidly evolving and facing unique challenges. Programs like those offered by NUS recognize this, aiming to provide a global education with a strong regional focus.
Investing in the Future of Healthcare
By prioritizing both clinical effectiveness and economic value, and by investing in the training of HEOR professionals, we can ensure that new drugs are used appropriately, maximizing their benefit to patients, caregivers, and society as a whole. This ultimately leads to more sustainable and equitable healthcare systems.